COMPANY PROFILE

Mablink Bioscience

Explore full profile

Transforming cancer immunotherapy with next generation ADCs

Lyon, FranceFounded 2018Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Mablink Bioscience

Mablink Bioscience S.A.S., founded in 2018 and based in France, specializes in the development of Antibody Drug Conjugates (ADCs), a new class of cancer drugs. The company leverages its patented PSARlink technology, which uses hydrophilic polysarcosine to overcome the hydrophobicity of cytotoxic payloads, thereby enhancing the overall hydrophilicity and stability of ADCs. This technology allows for a higher Drug-to-Antibody Ratio (DAR) of up to 16, optimizing the therapeutic index and efficacy against tumor cells. Mablink serves pharmaceutical companies and research institutions focused on oncology, offering a platform that can be easily integrated into various stages of ADC development. The company generates revenue through partnerships and licensing agreements, providing its proprietary technology and expertise to enhance the development of targeted cancer therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2018
Headquarters: Lyon, France
Employees: 35
Open positions: None listed
Dealroom signal: 58.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	Oct 2023	$0	—	Eli Lilly	↗
SERIES A✓Equity / VC	Oct 2022	$34M	$136M	Elaia · Fondation Fournier-Majoie · Crédit Agricole · Pertinence Invest	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Mablink Bioscience website traffic

Latest recorded traffic for Mablink Bioscience is 60 monthly website visits, down 88% over the last three months.

Latest monthly visits60 3-month web change-88%

Monthly website visitsOct 2020–Sep 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTafalgie TherapeuticsNext-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals	Marseille, France	Operational	29	$18M	$53M
ETEgle TherapeuticsEgle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones	Paris, France	Operational
LTLys TherapeuticsInnovative biotherapies targeting neurological diseases with a focus on stroke and multiple sclerosis	Caen, France	Operational
CTCyllene TherapeuticsNon-replicating HSV-1 gene therapy for neurological diseases.	Paris, France	Operational
INInnoSkelA pioneering biotechnology company developing therapies for rare skeletal diseases	Valbonne, France	Operational
KIKimialysDeveloper of an analytical device intended to offer products based on innovative surface chemistry in the field of biosensors	Paris, France	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational